journal of gastric cancer

Nanoparticles to Deal with Gastric Cancer

Posted on Updated on

Gastric cancer, a multifactorial disease is one of the leading causes of death worldwide. Among all other cancers it ranks in number four because of its occurrence. Several factors are involved behind this deadly disease.

Factors involve in gastric cancer occurrence
Factors involve in gastric cancer occurrence

The factors could be environmental, bacterial or it could be host related. Some of the ethnic groups are more prone to this disease in comparison with others. Factors that could be responsible for gastric cancer occurrence. Though the number of gastric cancer incidents are getting low in the Western countries, which has been observed from the past few years, but still it remains pretty high in Asian region i.e. Korea, Japan. Read More>>>>>>>

Advertisements

Prognostic Factors in Advanced Gastric Cancer Patients With Suprapancreatic Lymph Node Metastasis

Posted on Updated on

Lymph node (LN) metastasis is one of the most important prognostic factors for patients after gastrectomy. In Asian countries, gastrectomy with extended (D2) lymphadenectomy is performed as a standard procedure for advanced gastric cancer, whereas gastrectomy with perigastric (D1) lymphadenectomy is used in western countries.

Kaplan-Meier
Kaplan-Meier

Whether gastrectomy with D2 lymphadenectomy improves the survival of patients with advanced gastric cancer remains controversial. The prognosis of gastric cancer patients with extended metastatic LNs is thought to be worse than that of patients without metastasis. The extended LNs of gastric cancer mainly consist of LNs along the common hepatic and splenic arteries.  Read More>>>>>

The Efficacy of Cytoreductive Surgery with Systemic Chemotherapy for Gastric Cancer with Peritoneal Dissemination

Posted on

Gastric cancer is the second leading cause of cancer death worldwide, although patient survival has improved because gastrectomy with D2 lymphadenectomy was adopted as a standard treatment.

Peritoneal Dissemination
Peritoneal Dissemination

However, the outcomes of patients with unresectable or recurrent gastric cancer remain poor, as more than 50% of potentially curable advanced gastric cancer patients die because of peritoneal recurrence. The median overall survival time for gastric cancer patients with peritoneal dissemination is >6 months. Although overall survival time is improved by systemic chemotherapy compared with best supportive care, there is currently no standard treatment regimen for gastric cancer with peritoneal dissemination. Read more>>>>>>>>>>>>>>>>>>>>

Neoadjuvant and Adjuvant Therapy for Gastrointestinal Tumors

Posted on

Prior to 2000 and the discovery of cKIT, the number of new GIST cases in the United States had been under diagnosed and therefore underestimated. With recent advances in understanding the biology and molecular pathogenesis of this tumor, differentiation of this tumor type from other gastrointestinal sarcomas has become more definitive.

art-10

The estimated incidence of new cases of GIST arising in the United States annually is now believed to range between 3,000 and 8000 cases annually. A population-based study to define the incidence of GIST using current criteria has reported an incidence of approximately 15 cases per million populations. GIST occurs predominantly in adult men and women between 50-80 years of age, median age of 58 years, but it can occur across the age spectrum, with a slight male predominance.  Read more>>>>>>>>>>>

The Efficacy of Cytoreductive Surgery with Systemic Chemotherapy for Gastric Cancer with Peritoneal Dissemination

Posted on Updated on

Gastric cancer is the second leading cause of cancer death worldwide, although patient survival has improved because gastrectomy with D2 lymphadenectomy was adopted as a standard treatment. However, the outcomes of patients with unresectable or recurrent gastric cancer remain poor, as more than 50% of potentially curable advanced gastric cancer patients die because of peritoneal recurrence.

Gastric Cancer

The median overall survival time for gastric cancer patients with peritoneal dissemination is >6 months. Although overall survival time is improved by systemic chemotherapy compared with best supportive care, there is currently no standard treatment regimen for gastric cancer with peritoneal dissemination. In 2008, a randomized phase III study of S-1 alone vs.  Read more>>>>>>>>>>>>>>

Prognostic Factors in Advanced Gastric Cancer Patients With Suprapancreatic Lymph Node Metastasis

Posted on Updated on

Lymph node (LN) metastasis is one of the most important prognostic factors for patients after gastrectomy. In Asian countries, gastrectomy with extended (D2) lymphadenectomy is performed as a standard procedure for advanced gastric cancer, whereas gastrectomy with perigastric (D1) lymphadenectomy is used in western countries. Whether gastrectomy with D2 lymphadenectomy improves the survival of patients with advanced gastric cancer remains controversial. The prognosis of gastric cancer patients with extended metastatic LNs is thought to be worse than that of patients without metastasis. The extended LNs of gastric cancer mainly consist of LNs along the common hepatic and splenic arteries.

Suprapancreatic Lymph Node Metastasis
Suprapancreatic Lymph Node Metastasis

Generally, the survival benefits of LN dissection and the incidence of complications are important for choosing the type of operation. Previously, we reported that patients with advanced gastric cancer with metastatic suprapancreatic LNs have poor prognoses. The purpose of dissecting suprapancreatic LNs is to ensure complete clearance of local cancer cells to improve patient prognosis. Read more………………..

Neoadjuvant and Adjuvant Therapy for Gastrointestinal Tumors

Posted on

Prior to 2000 and the discovery of cKIT, the number of new GIST cases in the United States had been under diagnosed and therefore underestimated. With recent advances in understanding the biology and molecular pathogenesis of this tumor, differentiation of this tumor type from other gastrointestinal sarcomas has become more definitive. The estimated incidence of new cases of GIST arising in the United States annually is now believed to range between 3,000 and 8000 cases annually.

art-10
Adjuvant Therapy for Gastrointestinal Tumors

A population-based study to define the incidence of GIST using current criteria has reported an incidence of approximately 15 cases per million populations. GIST occurs predominantly in adult men and women between 50-80 years of age, median age of 58 years, but it can occur across the age spectrum, with a slight male predominance. The malignant potential of GIST neoplasm is quite varied. Forty percent of cases that are localized at presentation will become metastatic, and 10-20% of cases will present as metastatic disease. Read more………………….